To begin understanding the differential clinical impact of DNMT3A mutations relative to FLT3 and NPM1 on outcomes in de novo AML, including AMLDNMT3A/FLT3/NPM1, we then turned our attention to multivariate analysis. This evidence concerns the gene FLT3 and acute myeloid leukemia.